De Beers' 1947 slogan, "A diamond is forever," revolutionized the industry. The ad campaign established diamonds as the most romantic purchase, and the status is still paying off. However, what about their value as investments? Are diamonds really forever?
Mint asked experts to share investing lessons from diamonds' two-decade-long price stagnation and whether modern-day assets like cryptocurrencies will meet the same fate.
Radhika Gupta, MD and CEO, Edelweiss Asset Management Ltd
The key thing is some asset classes can structurally be in decline and not deliver any returns for over 20 years. Commodities are a clear example of this as prices depend on supply and demand, and there's no inherent reason for them to grow over time.
For instance, the diamond market has been disrupted by lab-grown diamonds, which have reduced demand and impacted the value of natural diamonds. This shows how changes in market dynamics or technological advancements can lead to prolonged price stagnation or even a decline.
Unlike equities, commodities don't have a natural growth trajectory and are not long-only assets as they don't create value through advancement.
Equities are different. In a growing economy, firms drive growth through innovation, expansion and productivity, creating long-term value for shareholders, making equities more reliable for wealth creation over time.
While commodities can have a role in a portfolio for diversification or as a short-term hedge against inflation, they are unlikely to deliver steady, long-term growth. Relying on them as the primary driver of wealth may lead to disappointing results.
ãã®èšäºã¯ Mint Bangalore ã® January 02, 2025 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ Mint Bangalore ã® January 02, 2025 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³
Nvidia Shows New Chips, Inks Toyota Deal for Robotic Cars
Shares of Toyota, Nvidia's suppliers rise on optimism about the AI chip maker's prospects
DIAL drops plea over Hindon ops expansion
Delhi International Airport Ltd (DIAL) on Tuesday withdrew its legal challenge against the Centre's decision to allow the Airports Authority of India (AAI) to operate scheduled commercial flights from the Indian Air Force Station in Hindon, Ghaziabad.
Auto sales rise 9% in 2024 despite headwinds: Fada
Inventory build-up, delayed harvest payments, weak consumer sentiment weighed on demand in Dec
Razorpay Charts Return to India; Eyes Expansion, IPO
Firm is likely to complete its reverse-flip in six months, with an IPO expected in two years
Bank profits set to moderate in FY26 as bad assets rise
Ind-Ra sharply revised down its FY25 system credit growth estimate to 13-13.5% from 15% earlier
Lloyds Metals shines on likely gains from acquisition, capex
Lloyds Metals & Energy Ltd's shares have gained about 15% so far in 2025 after the company's quarterly update and announcement of employee stock options (Esops) for its 6,000 workers.
Another tough year for FMCG?
Feeling blue
Your fancy, new ETF might be a little too fancy
Exchange-traded funds have mostly been great investments, but they are getting too complex for their own good
Risks to economy escalating in 2025, cautions SBICAPS
Rising household debt, fluctuating FII flows among risks that threaten to amplify economic fragility: Report
Intas Pharma bags another overseas company
Gujarat-based drug-maker Intas Pharmaceuticals Ltd., which counts private equity firm ChrysCapital, Singapore state investment firm Temasek, and Abu Dhabi Investment Authority (ADIA) as its investors, has signed a deal to acquire a biologic medication brand from US-based Coherus Biosciences.